Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALBO Albireo Pharma	$44.15	$44.17	$16.02 ▼ $45.23	$913.91M	1.03	704,539 shs	1.24 million shs
CTMX CytomX Therapeutics	$2.42 -6.9%	$2.24	$0.40 ▼ $3.10	$209.62M	2.05	2.22 million shs	1.54 million shs
INVVY Indivior	$21.85 -1.8%	$21.85	$14.76 ▼ $35.50	$3.01B	0.35	3,825 shs	8,100 shs
MNKD MannKind	$3.77 -0.8%	$4.10	$3.51 ▼ $7.63	$1.15B	0.96	2.44 million shs	1.82 million shs
STSA Satsuma Pharmaceuticals	$1.10	$1.08	$0.59 ▼ $8.08	$36.47M	0.1	701,788 shs	N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALBO Albireo Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
CTMX CytomX Therapeutics	-6.92%	-2.81%	-14.18%	+354.46%	+84.73%
INVVY Indivior	0.00%	0.00%	0.00%	0.00%	0.00%
MNKD MannKind	-0.79%	+4.58%	-2.84%	-19.10%	-31.83%
STSA Satsuma Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	4.2699 of 5 stars	3.5	1.0	0.0	4.7	2.9	1.7	1.3
INVVY Indivior	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	2.4229 of 5 stars	3.6	0.0	0.0	0.0	1.6	1.7	1.9
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALBO Albireo Pharma	0.00	N/A	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.33	120.39% Upside
INVVY Indivior	0.00	N/A	N/A	N/A
MNKD MannKind	3.29	Buy	$10.33	174.09% Upside
STSA Satsuma Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest STSA, ALBO, MNKD, INVVY, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALBO Albireo Pharma	$40.58M	22.52	N/A	N/A	$9.11 per share	4.85
CTMX CytomX Therapeutics	$138.10M	1.41	$0.34 per share	7.18	($0.01) per share	-242.00
INVVY Indivior	$791M	3.81	$1.15 per share	18.94	$1.45 per share	15.07
MNKD MannKind	$297.60M	3.85	$0.14 per share	27.38	($0.29) per share	-13.00
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALBO Albireo Pharma	-$34.03M	-$6.72	N/A	N/A	N/A	-228.51%	-97.13%	-46.89%	N/A
CTMX CytomX Therapeutics	$31.87M	$0.48	5.04	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
INVVY Indivior	$205M	$1.05	20.81	12.00	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	$27.59M	$0.10	37.70	16.39	N/A	10.12%	-32.41%	10.85%	8/6/2025 (Estimated)
STSA Satsuma Pharmaceuticals	-$70.06M	-$2.01	N/A	N/A	N/A	N/A	-115.24%	-102.26%	N/A

Latest STSA, ALBO, MNKD, INVVY, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	MNKD MannKind	$0.04	N/A	N/A	N/A	$77.82 million	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
INVVY Indivior	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
STSA Satsuma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALBO Albireo Pharma	N/A	6.32	6.23
CTMX CytomX Therapeutics	N/A	1.73	1.73
INVVY Indivior	N/A	N/A	N/A
MNKD MannKind	N/A	2.36	2.11
STSA Satsuma Pharmaceuticals	N/A	7.44	7.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALBO Albireo Pharma	94.25%
CTMX CytomX Therapeutics	67.77%
INVVY Indivior	0.05%
MNKD MannKind	49.55%
STSA Satsuma Pharmaceuticals	93.26%

Insider Ownership

Company	Insider Ownership
ALBO Albireo Pharma	6.90%
CTMX CytomX Therapeutics	6.60%
INVVY Indivior	N/A
MNKD MannKind	2.70%
STSA Satsuma Pharmaceuticals	31.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALBO Albireo Pharma	130	20.70 million	19.27 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
INVVY Indivior	800	137.88 million	N/A	Not Optionable
MNKD MannKind	400	303.93 million	295.73 million	Optionable
STSA Satsuma Pharmaceuticals	21	33.15 million	22.81 million	Not Optionable

STSA, ALBO, MNKD, INVVY, and CTMX Headlines

Recent News About These Companies

Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting

June 19, 2025 | prnewswire.com

Durham-based Satsuma wins FDA approval for migraine treatment

May 21, 2025 | ncbiotech.orgN

Non-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsight

May 16, 2025 | theglobeandmail.com

FDA approves Atzumi for acute migraine treatment in adults

May 6, 2025 | healio.comH

FDA Okays Dihydroergotamine Nasal Spray for Acute Migraine

May 5, 2025 | medscape.comM

Nasal Powder for Acute Migraine Gets FDA Nod

May 2, 2025 | msn.com

FDA clears Satsuma’s Atzumi for migraine

May 2, 2025 | bioworld.comB

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi

May 1, 2025 | contractpharma.comC

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

April 30, 2025 | prnewswire.com

Satsuma Pharmaceuticals Inc (STSA)

April 10, 2025 | uk.investing.com

Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

November 26, 2024 | prnewswire.com

SNBL’s Subsidiary Resubmits Migraine Drug Application

October 31, 2024 | markets.businessinsider.com

Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura

October 30, 2024 | prnewswire.com

Aprea Therapeutics (NASDAQ:APRE) Stock Quotes, Forecast and News Summary

October 10, 2024 | benzinga.com

Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs

October 8, 2024 | prnewswire.com

Satsuma, AL Weather Conditions

August 21, 2024 | wunderground.comW

Satsuma pulped as acute migraine drug flunks phase 3 trial

August 9, 2024 | pharmaphorum.comP

Satsuma, FL Weather Conditions

July 29, 2024 | wunderground.comW

Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting

June 13, 2024 | prnewswire.com

With manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal spray

January 18, 2024 | fiercepharma.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

STSA, ALBO, MNKD, INVVY, and CTMX Company Descriptions

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

CytomX Therapeutics NASDAQ:CTMX

$2.42 -0.18 (-6.92%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.44 +0.02 (+0.83%)

As of 07/11/2025 07:44 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Indivior OTCMKTS:INVVY

$21.85 -0.40 (-1.82%)

As of 06/9/2023

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

MannKind NASDAQ:MNKD

$3.77 -0.03 (-0.79%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$3.78 +0.01 (+0.16%)

As of 07/11/2025 07:56 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time